Elsevier

The Lancet

Volume 352, Issue 9135, 10 October 1998, Pages 1194-1195
The Lancet

Research Letters
Lack of T-cell proliferative response to HIV-1 antigens after 1 year of highly active antiretroviral treatment in early HIV-1 disease

https://doi.org/10.1016/S0140-6736(05)60532-6Get rights and content

References (5)

  • ES Rosenberg et al.

    Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia

    Science

    (1997)
  • M Carlesimo et al.

    CD28 stimulation and T lymphocyte proliferative responses in HIV-1 infection

    Clin Exp Immunol

    (1998)
There are more references available in the full text version of this article.

Cited by (108)

  • Engineered DNA modifying enzymes: Components of a future strategy to cure HIV/AIDS

    2013, Antiviral Research
    Citation Excerpt :

    Particularly, long-term treatment frequently results in secondary complications, such as diabetes, hyperlipidemia, cardiovascular disease, osteoporosis, and chronic kidney disease (Calmy et al., 2009; Deeks and Phillips, 2009). More importantly, patients successfully treated with ART for several years still do not fully recover their immune responses, and show increased levels of immune activation along with its harmful effects (Ostrowski, 2010; Plana et al., 1998). Consequently, low-level viral replication may persist along with an established pool of latently infected cells (Finzi et al., 1997, 1999; Palmer et al., 2008).

  • Challenges in dendritic cells-based therapeutic vaccination in HIV-1 infection. Workshop in dendritic cell-based vaccine clinical trials in HIV-1

    2011, Vaccine
    Citation Excerpt :

    There is increasing evidence that a strong HIV-1-specific CD4+ helper T-cell response is crucial in order to achieve a sustained and effective HIV-1-specific CD8+ cytotoxic T-lymphocyte (CTL) response able to control HIV-1 replication both in the macaque model [10] and in humans [5,11,12] and this concept is entirely consistent with recent data on chronic viral infections in the mouse model [13]. Although HIV-1-specific CD8 T-cells and CD4 T-cells secreting interferon gamma (IFN-gamma) can be found in most HIV-1-infected individuals, the CD4 T-cell proliferative response is absent [4,6,12] and the cytolytic activity of CD8 T-cells is defective [14–16]. Some data suggest that the antigen presenting cell (APC) functions of dendritic cells (DC) are also impaired in HIV-1-infected patients and this could contribute to dysfunction in HIV-1-specific helper and CTL responses [17–19].

  • Ex vivo production of autologous whole inactivated HIV-1 for clinical use in therapeutic vaccines

    2011, Vaccine
    Citation Excerpt :

    Combined antiretroviral therapy (cART) inhibits HIV-1 replication to levels below the limit of detection of standard clinical assays, allowing the restoration of normal or nearly normal CD4 T cell counts and protective T cell immunity to opportunistic pathogens in most patients, and has dramatically reduced the morbidity and mortality of HIV-1 infection. However, in spite of these clinical benefits, cART is incapable of eradicating HIV-1, and also fails to restore HIV-specific T cell responses able to durably and effectively to control HIV-1 replication when antiretroviral drugs are discontinued [1–5]. Thus, cART must be administered for life, increasing the risk of drug-related adverse effects, the potential for emergence of drug resistant mutant viral variants, along with some inconvenience for the patients and economic burden for the patient and society [6,7].

View all citing articles on Scopus
View full text